S

San Juan Oncology Associates | Farmington, NM

Research site
(Unclaimed)
Location
2325 East 30th Street, Farmington, New Mexico, United States of America
Site insights

Top conditions

Non-Small-Cell Lung Carcinoma (14 trials)

Lung Cancer (12 trials)

Breast Cancer (11 trials)

Lymphoma (8 trials)

Leukemia (7 trials)

Top treatments

Trastuzumab
Obinutuzumab
Atezolizumab
Pertuzumab
Dexamethasone
Paclitaxel
Docetaxel
Lenalidomide
Erlotinib
Carboplatin

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

15 of 60
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies

This trial will look at a drug called SEA-CD70 with and without azacitidine, to find out if it is safe for patients with myelodysplastic syndrome (MD...

Enrolling
Myelodyspastic Syndrome
Acute Myeloid Leukemia
Drug: azacitidine
Drug: SEA-CD70

The purpose of this study to determine if the addition of daratumumab to bortezomib + lenalidomide + dexamethasone (VRd) will improve overall minimal...

Active, not recruiting
Multiple Myeloma
Drug: Lenalidomide
Drug: Daratumumab

This Phase III, randomized, double-blind, placebo-controlled, multicenter study will evaluate the efficacy and safety of giredestrant combined with p...

Active, not recruiting
Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
Drug: Letrozole
Drug: Giredestrant-matched Placebo

This Phase III, randomized, open-label, multicenter study will evaluate the efficacy and safety of giredestrant plus everolimus compared with the phy...

Enrolling
Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
Drug: Dexamethasone Mouth Rinse
Drug: LHRH Agonist

This study will evaluate the efficacy, safety, and pharmacokinetics of mosunetuzumab subcutaneous (SC) formulation in participants with selected B-ce...

Enrolling
Non-Hodgkin Lymphoma
Drug: Mosunetuzumab (Cohorts D-E)
Drug: Tocilizumab

The purpose of this study is to evaluate the efficacy and safety of atezolizumab in combination with tiragolumab compared with durvalumab in particip...

Active, not recruiting
Non-small Cell Lung Cancer (NSCLC)
Drug: Tiragolumab
Drug: Durvalumab

This clinical trial is studying solid tumor cancers. A solid tumor is one that starts in part of your body like your lungs or liver instead of your b...

Enrolling
HER2 Positive Breast Neoplasms
HER2 Low Breast Neoplasms
Drug: tucatinib
Drug: disitamab vedotin

The main aim is to evaluate the effect of Ixazomib in combination with lenalidomide and dexamethasone on Multiple Myeloma disease progression at 2 ye...

Active, not recruiting
Multiple Myeloma
Drug: Dexamethasone
Drug: Ixazomib

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor,...

Enrolling
Non Small Cell Lung Cancer
Biological: Telisotuzumab Vedotin
Drug: Docetaxel

The purpose of this study is to evaluate the clinical benefit of subcutaneous (SC) daratumumab administered in combination with standard multiple mye...

Active, not recruiting
Multiple Myeloma
Drug: Daratumumab
Drug: Prednisone

Multicenter, open-label, prospective treatment protocol that provides continued access to ibrutinib to subjects who have completed parent ibrutinib s...

Invitation-only
Solid Tumor
Graft Vs Host Disease
Drug: Ibrutinib

The study is researching an investigational drug, called BNT116, in combination with cemiplimab. BNT116 and cemiplimab will each be called a "study d...

Enrolling
Advanced Non-Small Cell Lung Cancer
Drug: Cemiplimab
Drug: BNT116

The primary objective of this study is to assess the efficacy of 2 different doses of onvansertib in combination with a chemotherapy regimen of irino...

Active, not recruiting
Metastatic Colorectal Cancer
Colorectal Cancer
Drug: Bevacizumab
Drug: Onvansertib

The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surg...

Enrolling
Triple Negative Breast Cancer
Drug: Capecitabine
Drug: Sacituzumab govitecan-hziy (SG)
Locations recently updated

This study compares rPFS in men with mCRPC treated with talazoparib plus enzalutamide vs. enzalutamide after confirmation of the starting dose of tal...

Active, not recruiting
mCRPC
Drug: Talazoparib with enzalutamide
Drug: Placebo with enzalutamide

Trial sponsors

Genentech logo

Genentech (12 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems